Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: An immunohistochemical analysis with automated cellular imaging

American Journal of Clinical Pathology

Volumn 118, Issue 2, 2002, Pages 194-201

  Maitra, Anirban ^a   Ashfaq, Raheela ^b   Gunn, Carla R ^a   Rahman, Ayman ^a   Yeo, Charles J ^a   Sohn, Taylor A ^a   Cameron, John L ^a   Hruban, Ralph H ^a   Wilentz, Robb E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase 2; Image analysis; Pancreatic adenocarcinoma; Pancreatic intraepithelial neoplasia; PanIN

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN;

ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UPREGULATION; ADENOCARCINOMA; ADULT; AGED; BIOSYNTHESIS; CARCINOMA IN SITU; ENZYMOLOGY; FEMALE; IMAGE PROCESSING; MALE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PRECANCER;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0036672963     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/TPG4-CK1C-9V8V-8AWC     Document Type: Article

References (37)

1. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972 .
2. Lowenfels AB, Maisonneuve P, Whitcomb EXT, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169-170.
3. Hruban RH, Petersen GM, Goggins M, et al. Familial pancreatic cancer. Ann Oncol. 1999;10:69-73.
4. Hruban RH, Wilentz RE, Goggins M, et al. Pathology of incipient pancreatic cancer. Ann Oncol. 1999;10:9-11.
5. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial ncoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol. 2001;25:579-586.
6. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 2000;60:2002-2006.
7. Wilentz RE, Chung CH, Sturm PD, et al. K-ras mutations in the duodenal fluid of patients with pancreatic carcinoma. Cancer. 1998;82:96-103.
8. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 2000;156:1767-1771.
9. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821-1825.
10. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502.
11. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-1316.
12. Dannenberg AJ, Zakim D. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2. Semin Oncol. 1999;26:499-504.
13. Bresalier RS. Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition. Gastroenterobgy. 2000;119:267-268.
14. Takaku K, Sonoshita M, Sasaki N, et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem. 2000;275:34013-34016.
15. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
16. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997-5001.
17. Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96:990-996.
18. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst. 1998;90:455-460.
19. Komhoff M, Guan Y, Shappell HW, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol. 2000;157:29-35.
20. Lee LM, Pan CC, Cheng CJ, et al. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res. 2001;21:1291-1294.
21. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal antiinflammatory drugs. Cancer Res. 1999;59:4356-4362.
22. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987-990.
23. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76.
24. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
25. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21:139-146.
26. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
27. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am. 1998;7:43-65.
28. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with P16INK4 mutations. N Engl J Med. 1995;333:970-974.
29. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360-5364.
30. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterobgy. 2000;119:1447-1453.
31. Lynch PM. COX-2 inhibition in clinical cancer prevention. Oncology (Huntingt). 2001;15:21-26.
32. Agoff SN, Crispin DA, Bronner MP, et al. Neoplasms of the ampulla of Vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol. 2001;14:139-146.
33. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science. 1997;278:1073-1077.
34. Bauer KD, de la Torre-Bueno J, Diel IJ, et al. Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging. Clin Cancer Res. 2000;6:3552-3559.
35. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of Her-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503.
36. Wilentz RE, Su GH, Dai JL, et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol. 2000;156:37-43.
37. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer: International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89:442-446.